Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration?

March 1, 2017 updated by: M.P.C. Grooteman, Amsterdam UMC, location VUmc

Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration? Feasibility Study in Preparation of the Convective Transport Study (CONTRAST II)

Two recent randomized controlled trials (RCT) on online hemodiafiltration (HDF) did not show a treatment effect on patient survival when compared with low- or high-flux hemodialysis. Interestingly, post-hoc (on treatment) analyses from both trials unequivocally showed reduced mortality in the patient group achieving the highest convection volumes. Moreover, a third trial recently found a significant 30% decrease in mortality when HDF was applied with a mean convection volume of 23.7 L per session, which was somewhat higher than the average volumes reached in the aforementioned trials. Altogether, these findings support the concept of a dose-response effect, in which a minimally delivered convection volume is required in order to show a survival benefit.

Hence, the question arises whether high convection volumes are achievable in the majority of patients. The aim of this study is thus to test the following hypothesis: high-volume (>22 liters per treatment) post-dilution on-line hemodiafiltration (HDF) is achievable in the majority (>75%) of patients treated with chronic intermittent hemodialysis. This will be done through the use of a dedicated standardized protocol, in which the three most important determinants of convection volume will be successively optimized: treatment time, blood flow rate and filtration fraction.

Study Overview

Detailed Description

Hemodialysis (HD) is the most common used renal replacement therapy worldwide. The main objective is the removal of excess fluid and toxic solutes from the patient. Despite the relative efficiency of modern dialyzers, HD remains inferior to normal kidney function, in part because of the inadequate clearance of so-called 'middle molecules'. In other words, 'uremic toxins' accumulate in chronic HD patients.

The role of middle molecular weight uremic toxins in the pathogenesis of many co-morbid conditions associated with end-stage renal disease is increasingly recognized. Hence, the hypothesis that their enhanced removal could convey a better survival has been proposed. Actually, HDF is the most effective modality in terms of solute removal, because solute transport is achieved by both diffusion (especially for small molecules) and convection (the most important clearance route for middle molecules). Although some convective transport can be achieved with high-flux HD, only in HDF can the amount of filtered volume reach values of 20 liters per session or more.

In line with this thinking, two RCTs comparing HDF to standard hemodialysis with either low- or high-flux membranes were performed. However, treatment assignment did not alter the primary outcome of all-cause mortality in neither of them. Interestingly, post-hoc analyses from both trials unequivocally showed reduced mortality in the patient group achieving the highest convection volumes. Whether these data result from so-called dose-targeting bias (the healthiest patients reaching the highest volumes) cannot be formally excluded, but it is noteworthy that these results remained after correction for known determinants of mortality. Moreover, careful examination of patients' baseline characteristics of the CONTRAST HDF cohort did not reveal a healthier profile among the high convection volume group.

Recently, a third trial found a significant 30% decrease in mortality when HDF was applied with a mean convection volume of 23.7 L per session, which was somewhat higher than the average volumes reached in the aforementioned trials (respectively 20.7 and 19.5 L per session). Altogether, these findings support the concept of a dose-response effect, in which a minimally delivered convection volume is required in order to show a survival benefit.

Hence, the question arises whether high convection volumes are achievable in the majority of patients. In a previous sub-analysis of CONTRAST, it was found that the most important determinants of achieved convection volume were treatment time and blood flow rate. Moreover, it was noted that convection volumes and filtration fraction (defined as the ratio of extracted plasma water flow rate to blood flow rate) differed markedly per participating center, suggesting different practice patterns. Thus, it is plausible that the optimization of these apparently seemingly modifiable factors, on an individual basis through a dedicated standardized protocol, could translate into a higher achieved convection volume.

The aim of this study is to test the following hypothesis: high-volume (>22 liters per treatment) post-dilution on-line hemodiafiltration (HDF) is achievable in the majority (>75%) of patients treated with chronic intermittent hemodialysis.

This study is a prospective observational study, in which all enrolled patients will be treated by post-dilution on-line HDF with the application of a standardized protocol aiming at maximizing the convection volume.

At the beginning of the study, each patient's usual dialysis parameters will serve as starting parameters. In addition, incident HDF patients will start with a filtration fraction of 25 % (or equivalent) on a post-dilution mode.

Then, convection volume will be increased stepwise by successively optimizing the three most important determining factors. First, treatment time will be increased to 4 h, if possible. Second, blood flow will be increased by 50 mL/min per treatment until a value 400 mL/min is reached, provided that pre-specified safety limits are respected. Third, filtration fraction will be increased by 2% per treatment up to a maximum of 33% or the maximally achieved value within safety limits. To take into account different settings between the various dialysis machines used by the participating centers, an easy-to-use conversion table will be provided to the nursing staff, allowing to find the parameter (substitution flow, substitution volume or substitution ratio) corresponding to the desired filtration fraction.

At the end of the step-up protocol, the achieved convection volume will be assessed and compared to the starting value. Additionally, a follow-up period of 8 weeks, in which the maximum values of the targeted parameters will be kept the same, will be observed in order to assess whether the high convective volumes can be maintained for a longer period.

Study Type

Observational

Enrollment (Actual)

86

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amsterdam, Netherlands
        • VUMC
      • Amsterdam, Netherlands
        • Academic Medical Center - Dianet
      • Amsterdam, Netherlands
        • Diapriva Dialyse Center
      • Eindhoven, Netherlands
        • Catharina Hospital
      • Groningen, Netherlands
        • Martini Hospital
      • Rotterdam, Netherlands
        • Maasstad Hospital
      • Utrecht, Netherlands
        • UMC Utrecht

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients treated with hemodialysis or hemodiafiltration recruited at dialysis units in 6-7 hospitals in the Netherlands

Description

Inclusion Criteria:

  • Patients treated with HD or HDF since >6 weeks, 3 times a week;
  • Patients able to understand the study procedures;
  • Patients willing to provide written informed consent.

Exclusion Criteria:

  • Current age < 18 years;
  • Severe incompliance to dialysis procedure and accompanying prescriptions (frequency and duration of dialysis treatment and fluid restriction);
  • Life expectancy < 3 months due to non-renal disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
optimization of HDF key parameters
The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).

First, patients actually receiving standard dialysis will be switched to post-dilution HDF.

Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.

Precisely, the following 3 parameters will successively be increased towards a maximal target:

  1. Treatment time (up to 4 hours per session);
  2. Blood flow rate (up to 400 mL/min;
  3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).

Maximal values for these parameters will be those achieved within pre-specified safety limits.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of patients with a convection volume of at least 22 liters per treatment
Time Frame: At the end of the step-up protocol (within 6 weeks from the start of the study)
At the end of the step-up protocol (within 6 weeks from the start of the study)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Achieved convection volume
Time Frame: At the end of the step-up protocol and after a 8-weeks maintenance phase
At the end of the step-up protocol and after a 8-weeks maintenance phase
Change in convection volume
Time Frame: At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
Change in other HDF parameters
Time Frame: At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
Increase in treatment time, blood flow rate and filtration fraction
At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
Change in dialysis system pressures
Time Frame: At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline
Change in dynamic venous, arterial, filter entrance and transmembrane pressures during treatment when the maximal convection volume is reached vs. baseline pressure values
At the end of the step-up protocol and after a 8-weeks maintenance phase, vs. baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Peter J Blankestijn, MD PhD, UMC Utrecht
  • Study Director: Michiel L Bots, MD PhD, Julius Center for Health Sciences and Primary Care, UMC Utrecht
  • Study Director: Marinus A van den Dorpel, MD PhD, Maasstad Hospital, Rotterdam
  • Study Chair: Menso J Nubé, MD PhD, Amsterdam UMC, location VUmc
  • Study Director: Piet M ter Wee, MD PhD, Amsterdam UMC, location VUmc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 28, 2013

Primary Completion (Actual)

March 6, 2015

Study Completion (Actual)

June 30, 2015

Study Registration Dates

First Submitted

June 6, 2013

First Submitted That Met QC Criteria

June 10, 2013

First Posted (Estimate)

June 13, 2013

Study Record Updates

Last Update Posted (Actual)

March 3, 2017

Last Update Submitted That Met QC Criteria

March 1, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • METc 2013/33
  • Not yet available (not yet available)
  • Not available yet

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Replacement Therapy

Clinical Trials on Optimization of HDF key parameters

3
Subscribe